Could iPSCs Enable “Off-the-Shelf” Cell Therapy?

Publication date: 13 June 2019Source: Cell, Volume 177, Issue 7Author(s): Diana CrowAn “off-the-shelf” cell therapy derived from induced pluripotent stem cells (iPSCs) has entered clinical trials in the United States. Other companies are following suit, harnessing iPSCs’ self-renewal ability to manufacture cell therapies that don’t require customization for each patient. But some experts aren’t sure such therapies are a good idea.
Source: Cell - Category: Cytology Source Type: research